Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Last Wednesday we covered Biogen telling Fierce Biotech it was becoming "the new Biogen" through external deals. Five days later the company wrote a billion dollar check for RayThera to prove it. That is not a coincidence. Biogen's leadership clearly had this deal in the works when they gave that interview, and the messaging was designed to prepare the market for exactly this kind of move. RayThera brings immunology assets into a company that has historically been defined by neuroscience (Spinraza, Tecfidera, Leqembi). The immunology expansion makes strategic sense because the autoimmune market is one of the largest in pharma, Biogen's neuroscience pipeline needs diversification, and the company has the commercial infrastructure to support a new therapeutic area. On the regulatory front, the UniQure Huntington's filing acceptance is a milestone worth celebrating. Two weeks ago the FDA said no. Last week it reversed course. Now the filing is formally in. Huntington's disease has no disease modifying treatments. If AMT 130 is approved, it would be one of the most important gene therapy approvals in history. And Moderna clearing the advisory committee on its flu vaccine is the final regulatory step before a potential approval decision. The mRNA platform is about to move beyond COVID. 👉 Read Full Analysis

🔮 What To Watch

🏢 Corporate

Biogen Buys RayThera for Up to $1B to Enter Immunology BIIB

Biogen announced the acquisition of RayThera for up to $1B on June 21, according to The Pharma Letter. The deal expands Biogen into immunology, adding pipeline assets that complement the company's neuroscience core. This is the most significant action to come out of Biogen's stated "new Biogen" strategy, which emphasizes external partnerships and acquisitions over internal discovery. Combined with the salanersen Breakthrough Therapy designation for SMA, the diranersen Phase 3 advancement in Alzheimer's (despite a Phase 2 miss), and the felzartamab consolidation from TJ Biopharma ($850M), Biogen has now deployed more than $2B in pipeline building this year. The question going forward is execution: can a company built on neuroscience successfully integrate and commercialize immunology assets?

🔬 Regulatory

FDA Accepts UniQure's Huntington's Gene Therapy Filing QURE

The FDA formally accepted UniQure's filing for AMT 130 in Huntington's disease for accelerated approval review, according to The Pharma Letter. This follows a remarkable regulatory reversal: the FDA initially demanded data from an additional trial, then reversed that demand last week, and has now accepted the existing dataset for review. Huntington's disease is a fatal neurodegenerative condition affecting approximately 30,000 Americans with no approved disease modifying treatment. AMT 130 uses an AAV5 vector to deliver a microRNA that reduces production of the mutant huntingtin protein believed to cause the disease. A regulatory decision could come by late 2026 or early 2027.

💊 Vaccines

Moderna mRNA Flu Vaccine Clears Advisory Committee MRNA

Moderna's experimental mRNA flu vaccine received a positive vote from an FDA advisory committee on Thursday, according to The Pharma Letter. Moderna shares closed up 3.5% at $63.96 on the news. This follows the positive FDA briefing documents we covered on Friday, which indicated the shot met key study goals in adults 65 and older. The advisory committee's endorsement is typically the final step before the FDA makes an approval decision. If approved, this would be the first mRNA seasonal flu vaccine on the U.S. market and would validate the mRNA platform beyond pandemic applications.

🔬 Clinical

Neumora Drops Lead Depression Drug After Phase 3 Failure

Neumora Therapeutics dropped development of navacaprant after the drug missed both primary and key secondary endpoints in a Phase 3 study for major depressive disorder, according to The Pharma Letter. The company had already cut 35% of its workforce the previous week. BioSpace reported the Phase 3 miss sent shares "spiraling" in premarket trading. The failure leaves Neumora without its most advanced clinical asset and raises questions about the company's path forward.

📊 Capital Markets

12 IPOs, $4.1B Combined, Largest Total Since 2021

BioPharma Dive reported that twelve biotechs have gone public in 2026, raising a combined $4.1B. This year's IPO class has accounted for five of the six largest new biotech stock offerings since 2022. The IPO window remains the healthiest in five years, driven by strong M&A premiums that give public market investors confidence in exit optionality, later stage companies entering the market, and sustained institutional appetite for differentiated science.

📋 The Week in Review

📅 The Week Ahead

Biogen's 2026 deal activity tells the story of a company that knows it needs to change:

Total deployed or committed: approximately $2B. The immunology entry through RayThera is the boldest move because it takes Biogen outside its historical comfort zone. Spinraza, Tecfidera, and Leqembi were all neuroscience drugs developed largely in house. RayThera represents a fundamentally different model: buy external science in a new therapeutic area and integrate it.

The risk: Biogen's commercial and medical affairs infrastructure is built for neurology. Immunology requires different physician relationships (rheumatologists, dermatologists, gastroenterologists), different payer dynamics, and different competitive positioning. Whether "the new Biogen" can execute in a new therapeutic area while simultaneously advancing neuroscience programs is the central strategic question.

💊 AMT 130: The Huntington's Milestone

The FDA's acceptance of UniQure's filing for AMT 130 represents one of the most significant regulatory milestones in neurodegenerative disease this year. Key context:

Huntington's disease has defeated every prior therapeutic approach. Antisense oligonucleotides (Roche's tominersen) failed in Phase 3. Small molecule huntingtin lowering agents have shown limited efficacy. Gene silencing approaches are still early stage.

AMT 130 uses an AAV5 vector injected directly into the brain to deliver a microRNA that reduces production of the mutant huntingtin protein. The approach is fundamentally different: rather than trying to manage symptoms or slow decline, it addresses the genetic root cause.

The accelerated approval pathway means the FDA will evaluate AMT 130 based on a surrogate endpoint (likely reduction in mutant huntingtin protein levels in cerebrospinal fluid) rather than requiring proof of clinical benefit, which takes years to demonstrate in a slowly progressive disease.

📊 BIO International: What to Expect

BIO International Convention runs June 22 to 25 in San Diego. It is the largest biotechnology partnering event in the world, typically drawing more than 20,000 attendees. Key themes for 2026:

🎯 Catalyst Calendar: Late June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →